Latest Europe News

Pengana Global Private Credit Trust (ASX – PCX) has announced an $82 million entitlement and shortfall offer at $2.00 per new unit, targeting a 7% annual cash distribution yield. The Trust offers diversified exposure to global private credit funds, primarily in the US and Europe, managed by Pengana Credit with Mercer Consulting as investment consultant.

Ava Risk Group has secured $0.9 million in contracts to deploy its Aura Ai-X fibre sensing technology for border protection in Latvia and a major Australian transport infrastructure project, underscoring growing demand in critical security sectors.

Pure Hydrogen Corporation reported FY2025 revenue growth alongside a significant non-cash impairment charge, while progressing its clean hydrogen vehicle technologies and planning a spinout of its Australian gas assets.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, citing a strong British pound and increased project activity in EMEA as key growth drivers.

Altech Batteries has partnered with AMPower to immediately market and distribute sodium nickel chloride batteries across Europe, Australia, and the USA, fast-tracking revenue ahead of its large-scale CERENERGY project in Germany.

Sprintex Limited has raised $1.5 million through a strategic placement to advance its ammonia-reduction technology in Europe, supported by pending orders worth €9.3 million. The funding underscores growing investor confidence amid tightening environmental regulations.

Vanguard Investments Australia has announced estimated distribution amounts for 20 of its ETFs, with payments scheduled for mid-October 2025. Investors can expect detailed income figures across Australian and international equity and fixed income funds.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

Anteris Technologies has gained shareholder approval for an ASX waiver allowing flexible capital raising and updated its PARADIGM trial timeline, now set to begin patient enrolment in Q4 2025 after addressing FDA requests.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.

CurveBeam AI Limited has secured A$6.5 million in new capital to fuel global growth of its HiRise™ weight-bearing CT scanner, deepen its partnership with orthopaedic giant Stryker, and advance a potential strategic deal in China.

CurveBeam AI has secured A$6.5 million through an institutional placement and completed a €10 million vendor financing facility to accelerate sales of its HiRise™ CT scanner. The company is also progressing a strategic partnership in China and advancing surgical robot validation.